A new breast cancer drug is showing some promise.
Younger women suffering from a common form of advanced breast cancer have experienced significantly improved survival rates when treated with the drug that targets cancer cells.
An international clinical trial study was conducted among 672 women under the age of 59 who received a drug called ribociclib in combination with a common form of hormone therapy.
70 percent of the women who took combination therapy were alive after 42 months according to the findings.
That’s compared to 46 percent for women who were treated with only the hormone therapy and a placebo.
Researchers say the study is significant because it looks at younger women who have not gone through menopause.
The study was funded by pharmaceutical manufacturer Novartis.
The drug, which is taken in pill form, costs over $12,000 a month.